Company Overview
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Why Investors Should Care
Generates a return on equity of 100.3%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -1.31% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -1.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)60.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 100.3%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BRVE Braveheart Bio, Inc. PHARMA | 29.41 | -21.95 | $2.15B | 0.00% | -5.36% | 100.27% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 5.00K | 15.05M |
| Operating Income | -5.00K | -15.05M |
| EBITDA | -5.00K | -15.05M |
| Interest Expense | - | - |
| Pretax Income | -99.00K | -14.28M |
| Tax Provision | - | - |
| Net Income | -99.00K | -14.28M |
| Diluted EPS | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | - |
| Gross Profit | - |
| Operating Expenses | 4.50M |
| Operating Income | -4.50M |
| EBITDA | -4.50M |
| Interest Expense | - |
| Pretax Income | -66.05M |
| Tax Provision | - |
| Net Income | -66.05M |
| Diluted EPS | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Total Assets | 89.35M |
| Current Assets | 89.28M |
| Cash & Equivalents | 89.16M |
| Inventory | - |
| Receivables | - |
| Total Liabilities | 155.22M |
| Current Liabilities | 5.24M |
| Long Term Debt | - |
| Total Debt | - |
| Total Equity | -65.87M |
| Shares Outstanding | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -2.01M |
| Investing Cash Flow | -33.57M |
| Financing Cash Flow | 124.74M |
| Capital Expenditure | -33.57M |
| Free Cash Flow | -35.58M |
| Net Change in Cash | 89.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | 100.3% |
| ROCE % | -5.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BRVE
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9aWUVyajRrNVBrOG9xbmRBbnRtZ2R1cW1PVHlUS0J0U29EWW9zdHZvRGV4YzNaZ2hOZ3NpR0Y1YU84VDZHMzJxU1lzdXRjNU5P?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Braveheart Bio (NASDAQ:BRVE) Trading Up 8% - Should You Buy? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPZGxEUVVUNVkyNTRJaS1MV2piakRrRC10T0FNdHRWSU9IWXhJeS1Edmp5bi0yYW9Sa0RZQXFEOU5ZcDFhMzE2ZExlTURwWjdRNWtNSnh5QTJVVm9oQUVqUlBqTmZ3NGNndTlTTE1YUFdpSFRpdUtVT3V1RlBWRlpZeldOek9ad3RydE5GZD…
Earnings Flash (BRVE) Braveheart Bio Posts Q2 Loss $2.51 per Share - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNaXhjN0ttY0VERlU2dnh2aDNPZnUzTE9SejFnRW5wcy1LYjFsczFXaEtNLVNnbUxPcFhBTmhJZzZqOS01VGlDcHlOUlR4X1lKNWdHTTEwd3lWVHhVN0NlMG93QjZhRGFNVWV1Q20ybWJoQTdsVXp4S2s5NlVucHpuNXBpSVV1X0hBcFZiLU…
Braveheart Bio (NASDAQ:BRVE) Releases Quarterly Earnings Results, Misses Estimates By $2.26 EPS - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNZ2VHTlRKLXZmNUVIdDNucHg5cU5haHRZSG5TQXNNRFNIZU83ekkxVGZ1MXU1cjFvX0lvMWhXMmtaeTBmb04yUzBkUHRwUXl4S21ha1NDTHZtelI5TTZPeDk3YXhXTTBEdUkzRVNZV0JObmtMU1J0YlNvMk5xM0l2VVoyb29BQ3poWkduZ2…
A biotech company's management will join a live webcast Sept. 10 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOSUstS3dUU2hrR0RtUWtUSGNIVHB2X0R0aVpWRy1JN0ZMUWRUNEFCa09VaFlzNVM1Vl83LVZFdHQzY3QxczdkTlFVVzFnTGx5QUdBZnBTV2RORjBhZHlfM2RSMXVBOGtRangxZnpwMHZFX04tS2lnaER0VnVtdll6Ui1NeURMTFFBWVJMeX…
Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOM1NtcnVYNENHNS1Wd1NSYlJwWjlPMDJWUV92amIxY2xWZzB5MTJaaGxhZnBlTGVvYnNmamVRZC16c2lUb1oyczFxZ1djRzdUdGxLUmhPNDdYMzJXV1pTS0VfaTd6enpybWJuUWkteGpOck1pSGNKVXk2dlBKdGV5TGZ0cmExTGNqLVFJdl…
BRVE — Frequently Asked Questions
What is the current share price of Braveheart Bio, Inc. (BRVE)?
As of 2026-09-19 21:16 PDT, Braveheart Bio, Inc. (BRVE) trades at $29.41 on NasdaqGM. Its 52-week range is $25.01 to $30.00.
What is the market capitalisation of BRVE?
Braveheart Bio, Inc. (BRVE) has a market capitalisation of $2.15B on NasdaqGM.
What is the P/E ratio of BRVE?
BRVE trades at a trailing price-to-earnings (P/E) ratio of -21.95. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -11.24.
What is the return on equity (ROE) of BRVE?
BRVE has a return on equity (ROE) of 100.27%. Its return on capital employed (ROCE) is -5.36%.
Is BRVE a good stock to buy?
This page provides a data-driven analysis of Braveheart Bio, Inc. (BRVE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.